a health system doing a pilot (even if paid) is not the same as them as a customer. they might be fine with the former yet never convert to a customer. this is ok for them but fatal to your startup. more healthcare founders are realizing this, but few realize the moves you

Close friend is looking for applied ML roles. Ideally West Coast, SoCal preferred, healthcare or biotech nice to have. PhD in ECE from top 5 institution. Currently research scientist at top academic medical center. Leads dev and deployment of DL models across multiple health

My 2024 predictions for biopharma software platforms: 1. Fewer new bioinformatics SaaS cos will be founded, funded, or alive by EOY. Customers and investors are saturated with many undifferentiated competitors. Slapping a GUI on top of an EC2 VM with a few ready-to-go RNASeq

because many medical papers are not good science and even if they were good, oracle god tier knowledge of science != good doctoring but several teams are trying this and it will probably be useful

biotech version of this is "x therapeutics" or "y biosciences". all you are doing is making your domain name and email addresses longer and harder to type.

I think we’re in a bubble

applied to founders: building a great product isn’t the goal when you are at the earliest stages of building your startup. great product is a side effect of the real goal, which is to see customers clearer than they see themselves. the goal is to see how to be meaningful to

Character Biosciences (characterbio.com) is hiring an Associate Director / Director of Data Science! This is a unique opportunity to work with an outlier team at an early stage on a promising techbio platform that will have enormous impact. About Character Biosciences -

Any good blog posts or tweets on the cost of various LIMS in 2024?

Founders are also conducting job interviews when they do “customer discovery”. They are interviewing someone for the role of customer, which is existentially important to eventually get right. No wonder the false positive rate is so high. Imagined demand is misconstrued as

Apparently you can use microfluidics to do PCR reactions of your sample in thousands of tiny droplets, analyze the melt curves using machine learning, and detect novel genotypes (not high-throughput sequencing) bmcbioinformatics.biomedcentral.com/articles/10.11…

Has anyone figured out how to disable Gemini in Gmail?

The primary existential threat common to all startups is the threat of indifference. When a baby is born the parents naturally care. But when a startup is born no one but the founders care. Parents are usually in a position to help their baby survive and grow. Founders can do

Small moves like "record inventories" can make a big difference to established firms. Yet these moves are non-obvious. If it were obvious, more people would do it. An analogously non-obvious move for startups is to find your customer. Founders agree this is a good idea. Yet, how

The argument for “founder mode” is attractive but suffers from confirmation bias. There are many examples of startups where (after finding demand) the founders hired leaders with relevant experience, delegated, and achieved even more success. Reality is nuanced.